ResearcherFujian Medical UniversityNo recent work listed

Jinluan Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3533-898X; OpenAlex author ID A5027737278. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper

Papers 2

Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α. Last author DOI 10.2147/ott.s187615 ↗
Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. First author DOI 10.1097/coc.0000000000000278 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vivek Verma · 1 shared paper, 2016 · strength 0.10
- Paper Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. DOI 10.1097/coc.0000000000000278 ↗
Chi H. Lin · 1 shared paper, 2016 · strength 0.10
- Paper Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. DOI 10.1097/coc.0000000000000278 ↗
Lirui Tang · 1 shared paper, 2018 · strength 0.09
- Paper Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-induci… DOI 10.2147/ott.s187615 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.